Page 81 - MEMORIA ANUAL 2020

PROGRAMA ESPAÑOL DE TRATAMIENTOS EN HEMATOLOGÍA (PETHEMA)
MEMORIA ANUAL 2020
SOCIEDAD ESPAÑOLA FUNDACIÓN ESPAÑOLA
DE HEMATOLOGÍA Y HEMOTERAPIA DE HEMATOLOGÍA Y HEMOTERAPIA
Maia C, Botta C, Garcés JJ, Peres C, Manrique I, Sarvide S, Rodríguez I, Alignani D, Zabaleta A, Burgos L, Merino J, Rodríguez S, López-López A, Puig N, Cedena MT, Paiva A, Rossi M, Tagliaferri P, Tassone P, Ghentile M, Borrello I, Rosinol Dachs L, Mateos MV, Lahuerta JJ, Bladé J, San-Miguel JF, Paiva B.
• A new risk stratification strategy in newly diagnosed multiple myeloma: an analysis on mature data from European clinical trials within the HARMONY big data platform.
25th Congress of the European-Hematology-Association (EHA). EHA25 virtual (JUN 10-21).
D’Agostino M, Lahuerta JJ, Waage A, Bertsch U, Zamagni E, Mateos MV, Larocca A, Dall’Olio D, van de Donk N. W, Salwender H, Bladé J, van der Holt B, Castellani G, Ciccone G, Durig J, Bring- hen S, Zweegman S, Cavo M, Goldschmidt H, Hernández Rivas JM, San Miguel J, Boccadoro M, Sonneveld P.
• How to define and predict unsustained CR in transplant-eligible multiple myeloma: a sub analysis of the GEM2012MENOS65 trial.
25th Congress of the European-Hematology-Association (EHA). EHA25 virtual (JUN 10-21).
Jiménez Ubieto A, Paiva B, Martínez López J, Cedena MT, Puig N, Oriol A, Blanchard MJ, Martínez R, Ríos R, Martín J, Sureda A, Hernández MT, de la Rubia J, González Medina J, Alonso R, Krsnik I, Palomera L, Moraleda JM, Bargay J, Gutiérrez N, Otero P, Mateos MV, Rosiñol L, San Miguel J, Bladé J, Lahuerta JJ.
• QIP-MASS spectrometry including free light chains in high-risk myeloma patients enrolled in the GEM-CESAR TRIAL: comparison with conventional and MRD disease IMWG response assessment.
25th Congress of the European-Hematology-Association (EHA). EHA25 virtual (JUN 10-21).
Puig N, Contreras T, Paiva B, Cedena MT, Pérez JJ, Aires I, Agulló C, Martínez-López J, Rodríguez- Otero P, González-Calle V, González MS, Oriol A, Gutiérrez NC, Ríos R, Rosiñol L, Álvarez MA, Ca- lasanz MJ, Bargay J, González AP, Alegre A, Escalante F, Martínez R, de la Rubia J, Teruel AI, de Arriba F, Palomera L, Hernández MT, López J, Martín J, García-Mateo A, García-Sanz R, Ocio EM, Bladé J, Lahuerta JJ, San Miguel JF, Mateos MV.
• Over ten years of f/u for phase 3 trial in smoldering myeloma at high risk of progression to myeloma: sustained TTP and OS benefit with RD versus no treatment.
25th Congress of the European-Hematology-Association (EHA). EHA25 virtual (JUN 10-21).
Mateos MV, Hernández MT, Salvador C, de la Rubia J, de Arriba F, López-Corral L, Rosiñol L, Paiva B, Palomera L, Bargay J, Oriol A, Prósper F, López J, Arguinano JM, Bladé J, Lahuerta JJ, San Miguel J.
81